Evkeeza (evinacumab-dgnb) ANGPTL3 antibody approved by FDA for children as young as one year old with homozygous hypercholesterolemia – Regeneron
Regeneron Pharmaceuticals, Inc. announced that the FDA has approved Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of… read more.
